J&J Finds Silver Lining in CMS Reimbursement Decision On ESAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Although disappointing, the CMS decision to eliminate Medicare reimbursement for some ESA uses has created an environment of greater certainty for planning purposes, J&J exec says.
You may also be interested in...
FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling
FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.
Committee Rejects FDA’s Proposed Treatment Target For ESAs
Hemoglobin target will depend on FDA’s acceptance of observational data to drive treatment.
Amgen Restructures Amid Anemic Aranesp Sales
Biotech will eliminate up to 2,600 jobs, prioritize R&D spend to achieve $1 billion to $1.3 billion in pre-tax savings.